Showing 5571-5580 of 5643 results for "".
- Sylentis Presents New Results for the Treatment of AMDhttps://modernod.com/news/sylentis-presents-new-results-for-the-treatment-of-amd/2480173/Sylentis presented preclinical results of a new topically administered molecule (SYL1801), indicated for the treatment of age-related macular degeneration (AMD), at the ARVO meeting. Sylentis presented the abstract “Topical administration of siRNA targeting NRARP as a new treatment
- Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucomahttps://modernod.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma
- Nicox Presents Scientific Data for NCX 667 at ARVOhttps://modernod.com/news/nicox-presents-scientific-data-for-ncx-667-at-arvo/2480179/Nicox announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held on April
- OWL: Advancing Diversity in Leadership Appoints New Executive Director, Gaynor Frieshttps://modernod.com/news/owl-advancing-diversity-in-leadership-appoints-new-executive-director-gaynor-fries/2480180/OWL: Advancing Diversity in Leadership announced that Gaynor Fries has been appointed Executive Director of the organization. Gaynor has been a key part of the support team behind OWL since July 2015. With a BA in Business Administration and a Certificate in Non-Profit Management from Duke
- Glaucoma Research Foundation Speeds Search for a Curehttps://modernod.com/news/glaucoma-research-foundation-speeds-search-for-a-cure/2480187/Glaucoma Research Foundation has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure. Commemorated at an April 24 annual dinner at the War Memorial in San F
- Call for Abstracts for Academy 2018 San Antonio Scientific Programhttps://modernod.com/news/call-for-abstracts-for-academy-2018-san-antonio-scientific-program/2480193/The Scientific Program Committee of the American Academy of Optometry invites the submission of abstracts for Academy 2018 San Antonio, to be held Wednesday, November 7 through Saturday, November 10. The Academy’s Scientific Program offers scientists, educators, and clinicians the opportuni
- Lighthouse Guild Behavioral Programs Focus on the Psychological Impact of Vision Loss, Traumatic Brain Injury and Other Disabilitieshttps://modernod.com/news/lighthouse-guild-behavioral-programs-focus-on-the-psychological-impact-of-vision-loss-traumatic-brain-injury-and-other-disabilities/2480194/For the millions of people who have vision loss, have suffered a traumatic brain injury (TBI), or have developed other physical disabilities due to accident or illness, the psychological impact can be devastating. To meet the needs of these patients, Lighthouse Guild, the leading not-for-profit v
- J&J Vision Introduces Artificial-Intelligence Powered Virtual Assistant for Contact Lenseshttps://modernod.com/news/jj-vision-introduces-artificial-intelligence-powered-virtual-assistant-for-contact-lenses/2480195/Johnson & Johnson Vision introduced Andy, a virtual assistant chatbot powered by artificial intelligence (AI). Andy is designed to help guide U.S. consumers throughout their Acuvue brand contact lens journey – from those considering contact lenses for the first time to long-term wearers. The
- Aerie Announces US Launch of Rhopressahttps://modernod.com/news/aerie-announces-us-launch-of-rhopressa/2480197/Aerie Pharmaceuticals announced that it has launched Rhopressa in the United States. Rhopressa is now in national and regional US pharmaceutical distributors, and patients have access to Rhopressa through their local pharmacies across the nation. “We are pleased to announce the availabilit
- ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DMEhttps://modernod.com/news/thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-in-combination-with-anti-vegf-for-treatment-of-dme/2480200/ThromboGenics announced that it has successfully enrolled the first patient in a phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis, Novartis), for the treatment of DME (NCT03499223). TH